Article

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma

2025-10-09

Abstract excerpt

<h4>ABSTRACT</h4> Cancer therapies are typically effective in subsets of patients, reflecting the molecular diversity of cancers and motivating the need for predictive biomarkers of response. Biomarker-guided therapy is increasingly useful in oncology, yet biomarker discovery remains complicated by the large number of molecular features that make it difficult to distinguish causal determinants from spurious assoc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bc59c1b6-8012-5fb2-a328-d13794aeda7f
DOI: 10.1101/2025.10.08.681217

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphomaDOI 10.1101/2025.10.08.681217Read

TCPGdb: A comprehensive T cell perturbation genomics database for identification of critical T cell regulatorsSemantic proximity Read

Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screeningSemantic proximity Read

A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugsSemantic proximity Read

Folate transporter dynamics and therapy with classic and tumor-targeted antifolatesSemantic proximity Read

In vivo CRISPR screens identify key modifiers of CAR T cell function in myelomaSemantic proximity Read

Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.Semantic proximity Read

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural MesotheliomaSemantic proximity Read

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell LinesSemantic proximity Read

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathwaySemantic proximity Read

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.Semantic proximity Read

Advances in Genomics for Drug Development.Semantic proximity Read

Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.Semantic proximity Read